pc ¹öÀüÀ¸·Î À̵¿ Áß [½ÃÀ庸°í¼­]¼¼°èÀÇ À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå : Á¦Ç°º°, À¯Çüº°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¹× ¿¹Ãø(2024-2032³â)
¼¼°èÀÇ À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå : Á¦Ç°º°, À¯Çüº°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¹× ¿¹Ãø(2024-2032³â)
Genetic Toxicology Testing Market, By Product, By Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óÇ°ÄÚµå : 1454126
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 298 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,618,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅؽºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,608,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,029,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.

ÁÖÀÇ : ¶óÀ̼±½º¿¡ µû¶ó ÀÚ·á ÀÌ¿ë ¹× Àμ⠵ Á¦¾àÀÌ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù.
ÀÚ¼¼ÇÑ ³»¿ëÀº ¶óÀ̼±½º ¼³¸í¹®( )À» Âü°íÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.



¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 31¾ï 1,600¸¸ ´Þ·¯°¡ µÇ¸ç, 2024³âºÎÅÍ 2032³â¿¡ °ÉÃÄ CAGR 10.5%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå - ½ÃÀå ¿ªÇÐ

In vitro ¹æ¹ýÀ» ÀÌ¿ëÇÑ Ã¢¾à ¹× ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹Ãø

À¯ÀüÀÚ µ¶¼º °Ë»ç´Â ½Å±Ô È­ÇÕ¹°ÀÇ ÀáÀçÀû À¯Àü µ¶¼ºÀ» Æò°¡Çϱâ À§ÇØ ½Å¾àÀÇ Ãʱ⠴ܰ迡¼­ Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. In vitro À¯Àü µ¶¼º ½ÃÇèÀº DNA ¼Õ»óÀ̳ª µ¹¿¬º¯À̸¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Â ¹°ÁúÀ» È®ÀÎÇÒ ¶§ Á¦¾à ȸ»ç¸¦ Áö¿øÇÏ¿© º¸´Ù ¾ÈÀüÇÑ ÀǾàÇ° Èĺ¸ÀÇ °³¹ßÀ» ¼±È£ÇÏ´Â °ÍÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ±× °á°ú Á¦¾à ¾÷°è´Â â¾àÀ» Áö¿øÇÏ´Â ¼ö´ÜÀ¸·Î AI¸¦ Á¡Á¡ È°¿ëÇÏ°Ô µÇ¾ú½À´Ï´Ù. Á¦¾à¾÷°è¿¡¼­´Â ½Å¾àÀÇ »ó½Ã¿¡ °É¸®´Â ½Ã°£°ú ºñ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ´Â ±â¼ú¿¡ ±â¾÷ÀÌ ÅõÀÚÇϱ⠶§¹®¿¡ 2025³â±îÁö AI¿¡ 30¾ï ´Þ·¯°¡ ÁöÃâµÉ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á´Â À¯ÀüÀÚ Á¶¼º¿¡ ±Ù°ÅÇØ °³º° ȯÀÚ¿¡ ¸ÂÃá ÀǷḦ ½Ç½ÃÇÏ´Â °ÍÀ¸·Î, ÇコÄÉ¾î ºÐ¾ß¿¡¼­ ±â¼¼¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ È­ÇС¤È¯°æ¾ÈÀü¼º ½ÃÇèÀÇ È®´ë°¡ ½ÃÀå¿¡ ¼ºÀå ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ±×·¯³ª °Ë»ç ¼­ºñ½º ºñ¿ëÀÌ ³ôÀ¸¸é ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®·Â

¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 10.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

Á¦Ç° ¼¼ºÐÈ­¸¦ ¹ÙÅÁÀ¸·Î 2023³â¿¡´Â ¼­ºñ½º°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸¿©ÁÙ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯Çüº°·Î´Â ½ÃÇè°ü³»°¡ 2023³âÀÇ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

¿ëµµº°·Î´Â 2023³â¿¡ Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö°¡ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î ºÏ¹Ì´Â 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

À¯ÀüÀÚ µ¶¼º °Ë»ç ¼¼°è ½ÃÀåÀº Á¦Ç°, À¯Çü, ¿ëµµ, Áö¿ª¿¡ µû¶ó ±¸ºÐµË´Ï´Ù.

½ÃÀåÀº Á¦Ç°¿¡ µû¶ó ¼¼ °¡Áö·Î ±¸ºÐµË´Ï´Ù : ½Ã¾à, ¼Ò¸ðÇ°, ºÐ¼®, ¼­ºñ½º. ¼­ºñ½º´Â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ¸¹Àº Á¦¾àȸ»ç¿Í È­Çоàǰȸ»ç´Â À¯ÀüÀÚ µ¶¼º ½ÃÇèÀ» Àü¹®ÀÇ ¼öŹ¿¬±¸±â°ü(CRO)¿¡ À§Å¹ÇÏ°í ÀÖÀ¸¸ç, ±×µéÀÇ Áö½Ä, ´É·Â, ¼³ºñ·ÎºÎÅÍ ÀÌÀÍÀ» ¾ò±â À§Çؼ­À̸ç, ±×°ÍÀÌ ½ÃÇè ¼­ºñ½º ½ÃÀåÀÇ È®´ë ¿¡ ¹ÚÂ÷¸¦ °¡ÇÏ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº À¯Çüº°·Î 2°³·Î ±¸ºÐµÈ´Ù: In vitro¿Í In vivo. In vitro ºÐ¾ß´Â ½ÃÀåÀÇ ´ëºÎºÐÀÇ Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. À¯ÀüÀÚ µ¶¼º ½ÃÇè ½ÃÀåÀº ƯÈ÷ In vitro ºÐ¼®¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, ±ÔÁ¦ Àǹ«È­, ±â¼ú Áøº¸, ºñµ¿¹° ½ÃÇè ¹æ¹ý¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡·Î Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó ¼¼ °¡Áö ºÎ¹®À¸·Î ºÐ·ùµË´Ï´Ù. ÀǾàÇ° ¹× »ý¸í °øÇÐ, ½ÄÇ° »ê¾÷, È­ÀåÇ° »ê¾÷ ¹× ±âŸ. ½ÃÀåÀÇ Áö¹èÀûÀÎ ºÐ¾ß´Â Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÔ´Ï´Ù. À¯ÀüÀÚ µ¶¼º °Ë»ç´Â Á¦¾à ¹× »ý¸í °øÇÐ »ê¾÷¿¡¼­ ¾ÈÀü¼º Æò°¡¸¦ º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ÀǾàÇ° °³¹ß ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ °úÁ¤¿¡¼­ ÀÇ»ç °áÁ¤¿¡ µµ¿òÀÌ µÇ´Â ±ÍÁßÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù.

À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå - Áö¸®Àû ÅëÂû

Áö¸®ÀûÀ¸·ÎÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ Áö¿ªÀ¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº »ç¾÷ È°µ¿¿¡ °ü¿©ÇÏ´Â ±¹°¡¿¡ µû¶ó Ãß°¡·Î ºÐÇҵ˴ϴÙ. ºÏ¹Ì, ÁÖ·Î ¹Ì±¹Àº ÀÌ Áö¿ª¿¡¼­ ÀǾàÇ°ÀÇ ¿¬±¸°³¹ß(R&D)ÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í Àֱ⠶§¹®¿¡ ½ÃÀåÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ°í ÀÖ½À´Ï´Ù. ¹Ì±¹Àº Á¦¾à»ê¾÷ÀÌ È°¹ßÇÑ Áö¿ªÀ¸·Î ´ë±â¾÷ Á¦¾àȸ»ç, »ý¸í°øÇбâ¾÷, ÀǾàÇ°°³¹ß¾÷¹«¼öŹ±â°ü(CRO) µîÀÌ ½Å¾à ¹× Ä¡·á¹ý ¹ß°ßÀ» À§ÇÑ ´ë±Ô¸ð ¿¬±¸°³¹ß¿¡ Àû±ØÀûÀ¸·Î ÀÓÇÏ°í ÀÖ½À´Ï´Ù. 2021³â ¹Ì±¹ Á¦¾à¾÷°èÀÇ ¿¬°£ ¸ÅÃâÀº 5,500¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. °Ô´Ù°¡ ¹Ì±¹ ÀǾà Åë°è¿¡ µû¸£¸é ¹Ì±¹ÀÎÀº 2022³â¿¡ 6,335¾ï ´Þ·¯¸¦ ¾à¿¡ ÁöÃâÇß½À´Ï´Ù. À¯·´ÀÌ ½ÃÀå ¼ºÀå¿¡¼­ µÎ ¹ø°·Î Å« Áö¿ªÀ» Â÷ÁöÇÏ´Â ÀÌÀ¯´Â ÀǾàÇ° »ç¿ëÀÌ Áõ°¡ÇÏ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.

À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå - °æÀï ±¸µµ:

À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå °æÀïÀº ÁÖ·Î ¼­ºñ½º Á¦°ø¾÷üÀÇ Ç°Áú°ú ¼÷·Ãµµ¿¡ ÁßÁ¡À» µÓ´Ï´Ù. CRO(ÀǾàÇ° °³¹ß ¾÷¹« ¼öŹ±â°ü)¿Í ÀÚ»ç ½ÇÇè½ÇÀº ¸ðµÎ ½ÇÀû, °úÇÐÀû Àü¹®Áö½Ä, Á¤È®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â °á°ú¸¦ Á¦°øÇÏ´Â ´É·ÂÀ» ¾îÇÊÇÔÀ¸·Î½á °æÀïÇÏ°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ µ¶¼º ½ÃÇèÀ» À§ÇÑ ÃÖ÷´Ü ±â¼ú°ú Ç÷§Æû¿¡ ÅõÀÚÇÏ´Â ±â¾÷Àº °æÀï ¿ìÀ§¸¦ Â÷ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â ³ôÀº 󸮷® ½ºÅ©¸®´×, ½ÃÇè°ü³» ºÐ¼®, °è»ê ¸ðµ¨¸µ°ú °°Àº Áøº¸°¡ Æ÷ÇԵ˴ϴÙ. ÀǾàÇ° °³¹ß Ãʱ⠴ܰ迡¼­ ¿¹Ãø µ¶¼ºÇÐ ¹× À§Çè Æò°¡ÀÇ Á߿伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó À¯ÀüÀÚ µ¶¼º ½ÃÇèÀ» À§ÇÑ µ¶Ã¢ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ±â¾÷¿¡ ÃæºÐÇÑ ±âȸ°¡ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå À¯ÀüÀÚ µ¶¼º °Ë»çÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå À¯ÀüÀÚ µ¶¼º °Ë»ç ¾÷°èÀÇ Á¶»ç

Á¦5Àå À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå : ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÁõÀÇ ¿µÇ⠺м®

Á¦6Àå À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå »óȲ

Á¦7Àå À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå : Á¦Ç°º°

Á¦8Àå À¯ÀüÀÚµ¶¼º°Ë»ç½ÃÀå : À¯Çüº°

Á¦9Àå À¯ÀüÀÚ µ¶¼º °Ë»ç ½ÃÀå : ¿ëµµº°

Á¦10Àå À¯ÀüÀÚµ¶¼º°Ë»ç½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : À¯ÀüÀÚ µ¶¼º °Ë»ç ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

JHS 24.04.02
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Genetic Toxicology Testing Market size was valued at USD 3,116 Million in 2023, expanding at a CAGR of 10.5% from 2024 to 2032.

Genetic toxicity testing requirements for pharmaceutical agents consist of a series of brief in vitro and in vivo tests intended to assess the potential of a clinical drug candidate to induce DNA damage. Undetected DNA damage in clinical trials poses a risk to the safety of patients and volunteers. Due to their short duration, cost-effectiveness, and high productivity for rodent carcinogens, genetic toxicity tests are employed early in the drug development process. Genetic toxicology is a field that seeks to comprehend how various physical and chemical agents can lead to DNA damage and how changes in genetic material result in mutations if left unrepaired. Various types of potentially harmful substances can instigate DNA rearrangements, including point mutations, genomic instability, and epigenetic modifications.

Genetic Toxicology Testing Market- Market Dynamics

Increasing focus on drug discovery and personalized medicine using in vitro methods is anticipated to drive the growth of market

Genetic toxicology testing plays a vital role in the initial phases of drug discovery as it evaluates the potential genotoxicity of novel chemical compounds. In vitro genetic toxicology tests aid pharmaceutical companies in identifying substances that could potentially cause DNA damage or mutations, allowing them to prioritize the development of safer drug candidates. Consequently, the industry is increasingly turning to AI as a means to support drug discovery. An intriguing statistic within the pharmaceutical industry is the projected expenditure of USD3 billion on AI by 2025, as companies invest in technology that has the potential to reduce the time and costs associated with bringing new drugs to the market. Personalized medicine, which involves tailoring medical treatments to individual patients based on their genetic composition, is gaining momentum in the healthcare sector. Additionally, the expansion of Chemical and Environmental Safety Testing presents growth opportunities for the market. However, the high cost of testing services may impede market growth.

Genetic Toxicology Testing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.5% over the forecast period (2024-2032)

Based on Product segmentation, Services was predicted to show maximum market share in the year 2023

Based on Type segmentation, In vitro was the leading type in 2023

Based on Application segmentation, Pharmaceutical & Biotechnology was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Genetic Toxicology Testing Market- Segmentation Analysis:

The Global Genetic Toxicology Testing Market is segmented on the basis of Product, Type, Application, and Region.

The market is segmented into three divisions according to Product: Reagents & Consumables, Assays, and Services. Services hold the largest share in the market. Numerous pharmaceutical and chemical firms opt to subcontract genetic toxicology testing to specialized contract research organizations (CROs) in order to benefit from their knowledge, capabilities, and facilities, thereby fueling the expansion of the testing services market.

The market is segmented into two categories according to Type: In vitro and In vivo. The in vitro sector holds the majority share in the market. The genetic toxicology testing market, particularly focusing on in vitro assays, is expected to experience sustained growth due to regulatory mandates, advancements in technology, and the rising preference for non-animal testing methods.

The market is categorized into three segments according to its application: Pharmaceutical & Biotechnology, Food Industry, Cosmetics Industry, and Others. The dominant sector in the market is Pharmaceutical and Biotechnology. Genetic toxicology testing plays a crucial role in ensuring safety assessment within the pharmaceutical and biotechnology industries. It provides valuable data that aids in decision-making during drug development and regulatory approval processes.

Genetic Toxicology Testing Market- Geographical Insights

Geographically, this market is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The market is predominantly dominated by North America, primarily the United States, owing to the significant number of pharmaceutical research and development (R&D) initiatives taking place in the region. The United States is home to a thriving pharmaceutical industry, housing major pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) that actively engage in extensive R&D efforts to discover new drugs and therapies. In 2021, the U.S. pharmaceutical industry generated a staggering USD550 billion in annual revenue. Furthermore, as per U.S. Pharmaceutical Statistics, Americans spent USD 633.5 billion on medication in 2022. Europe holds the second-largest region for market growth, attributed to the increasing utilization of pharmagenomincs.

Genetic Toxicology Testing Market- Competitive Landscape:

Genetic toxicology testing market competition primarily focuses on the quality and proficiency of service providers. Both contract research organizations (CROs) and in-house laboratories compete by showcasing their track record, scientific expertise, and capability to provide precise and dependable results. Companies that invest in cutting-edge technologies and platforms for genetic toxicology testing gain a competitive advantage. This encompasses advancements in high-throughput screening, in vitro assays, and computational modeling. As the significance of predictive toxicology and risk assessment grows in the early stages of drug development, there are ample opportunities for companies that offer inventive solutions for genetic toxicology testing.

Recent Developments:

In August 2022, Thermo Fisher Scientific, a global leader in scientific services, has introduced the Applied Biosystems HIV-1 Genotyping Kit with Integrase for research purposes. This assay is designed to analyze positive samples of the human immunodeficiency virus (HIV) to detect genetic variations that are resistant to common antiretroviral treatments.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GENETIC TOXICOLOGY TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Thermo Fisher Scientific, Inc.

Charles River Laboratories International, Inc.

Laboratory Corporation of America Holdings

Eurofins Scientific Group

Jubilant Pharmova Limited.

Syngene International Limited

Gentronix Ltd.

Inotiv Inc.

Creative Bioarray

MB Research Laboratories

Others

GLOBAL GENETIC TOXICOLOGY TESTING MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENETIC TOXICOLOGY TESTING MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENETIC TOXICOLOGY TESTING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL GENETIC TOXICOLOGY TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1.Genetic Toxicology Testing Market Overview

2.Executive Summary

3.Genetic Toxicology Testing Key Market Trends

4.Genetic Toxicology Testing Industry Study

5.Genetic Toxicology Testing Market: COVID-19 Impact Analysis

6.Genetic Toxicology Testing Market Landscape

7.Genetic Toxicology Testing Market - By Product

8.Genetic Toxicology Testing Market - By Type

9.Genetic Toxicology Testing Market - By Application

10.Genetic Toxicology Testing Market- By Geography

11.Key Vendor Analysis- Genetic Toxicology Testing Industry

12.360 Degree Analyst View

13.Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â